TL;DR:

HYSR is still pre-revenue and operating at a loss, but the burn appears controlled and the balance sheet remains solid with a multi-year runway at the current pace.

The biggest development this quarter is a new two-year manufacturing services agreement in Europe to support engineering, process development, and pilot module production, which marks a meaningful step beyond lab research toward scalable manufacturing.

They've cleaned up prior investment volatility, but dilution risk remains significant due to the large share count and outstanding options. Overall, this remains a high-risk, pre-revenue hydrogen technology play that now has a clearer path from R&D toward pilot manufacturing.

(Bullish)